AstraZeneca/Bristol's Diabetes Drug Priced On Par With First-In-Class Januvia
This article was originally published in The Pink Sheet Daily
Executive Summary
Docs may find it tough to tell apart up-and-coming Onglyza and Merck's first-in-class blockbuster Januvia.